Zometa Fights Breast Cancer Spread in Large Study
In a major trial, 1800 premenopausal women with early stage breast cancer on hormone therapy received Zometa or not. After three years none of the Zometa group relapsed or died 6 vs 9 percent relapse or death in controls, a 36 percent risk reduction, with similar side effects aside from more fever and bone pain in the Zometa group.
MENTIONED IN THIS ARTICLE
Chicago
Novartis AG
Claudine Isaacs
Georgetown University
Lombardi Cancer Center
Michael Grant
Medical University of Vienna
American Society of Clinical Oncology
Nancy Davidson
Johns Hopkins University
United States
Grant
FDA urges asthma patients to switch to CFC-free inhalers
The FDA warns that time is running out for CFC inhalers as of December 31. Patients should switch to HF A powered inhalers like Ventolin HFA Proventil HFA ProAir HFA or Xopenex HFA while noting taste feel priming and cleaning differences and higher costs. Armstrong Pharmaceuticals remains the last maker and will stop production before the deadline.
MENTIONED IN THIS ARTICLE
FDA
Washington
U.S
Food and Drug Administration
GlaxoSmithKline
Schering Plough
Teva
Sepracor
Armstrong Pharmaceuticals
Armstrong
Also Mentioned on This Page
Zometa
Ruan
Aaa
Seacoast Media Group
LOWES
Verizon
Vera Ay
cMichaels
Jcpenney
Skohls
Wal*mart
Wentworth
Douglass
the Works Family Health & Fitness Center
Rt. 108
Somersworth, NH
Wentworth-Douglass Hospital
Central Avenue
Dover
Wdhospital.com